Gene Therapy for Muscular Disorders
Evvnt Promotion / evvnt
21.02.2023 - 23.02.2023 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, USA
Time: 9:30 am to 4:30 pm
Kongressthemen
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
Wissenschaftliche Fach-Gesellschaft
Hanson Wade
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/1443975-3?pid=4832
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo and More
Brochure: https://go.evvnt.com/1443975-3?pid=4832
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo and More
Anfragen und Anmeldung:
https://go.evvnt.com/1443975-2?pid=4832
Frau Emily Birt
Gesundheitsversorgung, Public Health
Sprache
Englisch
Englisch
Kongressgebühr
USD 2599.00 - USD 5396.00
USD 2599.00 - USD 5396.00
Teilnehmer erwartet
1000
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
